已收盘 12-19 16:00:00 美东时间
-0.250
-3.40%
Gyre Therapeutics initiates Phase 1 trial of F230, a novel ETA receptor antagonist, for pulmonary arterial hypertension (PAH). The trial represents the company's entry into the PAH field with F230, designed to block ETA receptor and reduce pulmonary pressure.
06-10 11:00
Gyre Therapeutics completed an underwritten public offering of 2,555,555 shares of common stock at $9.00 per share, raising approximately $23.0 million in gross proceeds. The company plans to use the net proceeds to advance its Phase 2 clinical trial of F351 in MASH-associated liver fibrosis, as well as for research, development, manufacturing, and general corporate purposes. Jefferies LLC acted as lead book-running manager, and H.C. Wainwright & Co. served as co-manager for the offering.
05-29 20:01
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesd...
2024-09-18 21:57
U.S. stocks were mostly higher, with the Dow Jones index gaining around 150 points on Monday. Shares of Galapagos NV (NASDAQ:GLPG) rose sharply during Monday's session after Ecor1 Capital reported a 9.9% stake in the company. Galapagos shares jumped 10% to $28.47 on Monday. Here are some other big s...
2024-08-26 21:59